EGCG inhibits pressure overload‐induced cardiac hypertrophy via the PSMB5/Nmnat2/SIRT6‐dependent signalling pathways

Yi Cai,Shan Shan Yu,Yang He,Xue Ying Bi,Si Gao,Ting Dong Yan,Guo Dong Zheng,Ting Ting Chen,Jian Tao Ye,Pei Qing Liu
DOI: https://doi.org/10.1111/apha.13602
IF: 7.523
2021-01-07
Acta Physiologica
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aim</h3><p>Epigallocatechin‐3‐gallate (EGCG), the major polyphenol found in green tea, exerts multiple protective effects against cardiovascular diseases, including cardiac hypertrophy. However, the molecular mechanism underlying its anti‐hypertrophic effect has not been clarified. This study revealed that EGCG could inhibit pressure overload‐induced cardiac hypertrophy by regulating the PSMB5/Nmnat2/SIRT6‐dependent signaling pathway.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Quantitative real‐time polymerase chain reaction and western blotting were used to determine the expression of mRNA and protein, respectively. A fluorometric assay kit was used to determine the activity of SIRT6, a histone deacetylase. Luciferase reporter gene assay and electrophoretic mobility shift assay were employed to measure transcriptional activity and DNA binding activity, respectively.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>EGCG could significantly increase Nmnat2 protein expression and enzyme activity in cultured neonatal rat cardiomyocytes stimulated with angiotensinⅡ (AngⅡ) and heart tissues from rats subjected to abdominal aortic constriction. Nmnat2 knockdown by RNA interference attenuated the inhibitory effect of EGCG on cardiac hypertrophy. EGCG blocked NF‐κB DNA binding activity induced by AngⅡ, which was dependent on Nmnat2 and the subsequent SIRT6 activation. Moreover, the activation of PSMB5 (20S proteasome subunit β‐5, chymotrypsin‐like) was required for EGCG‐induced Nmnat2 protein expression. Additionally, we demonstrated that EGCG might interact with PSMB5 and inhibit the activation of the proteasome.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These findings serve as the first evidence that the effect of EGCG against cardiac hypertrophy may be, at least partially, attributed to the modulation of the PSMB5/Nmnat2‐dependent signaling pathway, suggesting the therapeutic potential of EGCG in the prevention and treatment of cardiac hypertrophy.</p></section>
physiology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore how epigallocatechin - 3 - gallate (EGCG) inhibits cardiac hypertrophy caused by pressure overload by regulating the PSMB5/Nmnat2/SIRT6 - dependent signaling pathway. Specifically, the study aims to reveal the molecular mechanism of EGCG in the prevention and treatment of cardiac hypertrophy, especially how it exerts its anti - cardiac - hypertrophy effect by increasing Nmnat2 protein expression and activity and activating SIRT6. ### Research Background Cardiac hypertrophy is a morphological adaptive response of the heart to chronic overload of work load, mainly manifested as an increase in cardiomyocyte volume, enhanced protein synthesis, and re - expression of the fetal heart gene program. Although cardiac hypertrophy is initially a compensatory mechanism, long - term pathological cardiac hypertrophy may lead to an increased risk of heart failure and premature death. Although progress has been made in understanding the molecular mechanisms of cardiac hypertrophy, its pathogenesis is still not fully understood. ### Research Objectives 1. **To determine whether EGCG can prevent cardiac hypertrophy by regulating NAD+ synthase and the subsequent NAD+ - dependent signaling pathway**. 2. **To explore the specific mechanism by which EGCG inhibits cardiac hypertrophy by regulating the PSMB5/Nmnat2/SIRT6 - dependent signaling pathway**. ### Main Findings - **EGCG can significantly inhibit cardiac hypertrophy in both in vitro and in vivo experiments**: EGCG pretreatment can dose - dependently reduce the increase in the surface area of Ang II - induced cardiomyocytes and significantly inhibit the expression of atrial natriuretic peptide (ANF), brain natriuretic peptide (BNP), and β - myosin heavy chain (β - MHC) genes. - **EGCG increases Nmnat2 protein expression and activity**: EGCG can significantly increase Nmnat2 protein levels and NAD+ synthesis activity, while other Nmnat isoforms and Nampt have no significant changes. - **EGCG inhibits the decrease in Nmnat2 levels and NAD+ content in Ang II and AAC models**: EGCG pretreatment can reverse the decrease in Nmnat2 protein levels and enzyme activity induced by Ang II. - **Nmnat2 is involved in the inhibitory effect of EGCG on cardiac hypertrophy**: After knocking down Nmnat2, EGCG cannot inhibit the increase in the surface area of Ang II - induced cardiomyocytes and the expression of hypertrophy markers. - **EGCG increases the enzyme activity of SIRT6 by activating Nmnat2**: EGCG can reverse the decrease in SIRT6 activity caused by Ang II, and knocking down Nmnat2 will inhibit this effect. - **EGCG inhibits NF - κB DNA - binding activity and transcriptional activity by regulating the Nmnat2 - SIRT6 pathway**: EGCG pretreatment can significantly inhibit Ang II - induced NF - κB - Luc reporter gene activity, and knocking down Nmnat2 or SIRT6 will weaken this inhibitory effect. - **EGCG increases Nmnat2 protein expression by inhibiting PSMB5**: EGCG can inhibit the activity of the 20S proteasome, especially its β5 subunit (PSMB5), thereby increasing Nmnat2 protein expression. ### Conclusion These findings prove for the first time that EGCG inhibits cardiac hypertrophy by regulating the PSMB5/Nmnat2 - dependent signaling pathway, which provides new insights into the potential application of EGCG in the prevention and treatment of cardiac hypertrophy.